Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Pharmaceutical latest

A year of change for the US FDA: An update on notable pilots and programmes
2025-12-15T12:42:00+00:00
Cross-functional strategies in clinical data disclosure for EMA Policy 0070 and Health Canada PRCI
2025-12-15T12:41:00+00:00
From laboratory to patient: The role of New Substance Notifications in delivering innovative therapies in Canada
2025-12-15T12:40:00+00:00
Regulatory Rapporteur December 2025 – Contents
2025-12-15T12:06:00+00:00
2025 Regulatory Intelligence Conference Europe: Meeting report
2025-12-11T12:44:00+00:00
North America: Transparency, transformation and innovation pathways
2025-12-11T12:01:00+00:00

EMA ETF offers scientific advice for antimicrobial resistance
2025-11-21T16:20:00+00:00
SME1: Regulatory updates for SMEs, academia and start-ups
2025-11-18T09:59:00+00:00
PS2: Navigating the green horizon – Environmental sustainability and regulatory affairs
2025-11-18T09:58:00+00:00
PS1: Tailored development of biosimilars without efficacy and safety studies – Is this the future?
2025-11-18T09:58:00+00:00
HM10: Strengthening Europe’s clinical trials competitiveness
2025-11-18T09:58:00+00:00
HM9: From barrier to bridge – Practical strategies for successful advanced therapy medicinal product (ATMP) development
2025-11-18T09:57:00+00:00
HM8: ePI is on FHIR – Preparing for implementation
2025-11-18T09:57:00+00:00
HM7: First experiences with the HTA Regulation
2025-11-18T09:57:00+00:00
HM3: Applying Artificial Intelligence in real life
2025-11-18T09:44:00+00:00
HM2: Fireside chat
2025-11-18T09:44:00+00:00
November 2025 – Contents: Human medicines sessions
2025-11-17T15:42:00+00:00
Regulatory Rapporteur November 2025 – Contents
2025-11-17T15:09:00+00:00

More pharmaceutical content